Related references
Note: Only part of the references are listed.Rapid Response to Vedolizumab Therapy in Biologic-Naive Patients With Inflammatory Bowel Diseases
Brian G. Feagan et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2019)
Effect of vedolizumab on surgical rates in IBD: post hoc analysis from the GEMINI trials
B. G. Feagan et al.
JOURNAL OF CROHNS & COLITIS (2019)
Shorter Disease Duration Is Associated With Higher Rates o f Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis
David M. Faleck et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2019)
Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease
A. Barre et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease
Parambir S. Dulai et al.
GASTROENTEROLOGY (2018)
Patient Characteristics and Clinical Outcomes in Biologic-Naive Patients With Crohn's Disease Initiating Vedolizumab Treatment Early Versus Later After Diagnosis
Patel Haridarshan et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2018)
The safety of vedolizumab for ulcerative colitis and Crohn's disease
Jean-Frederic Colombel et al.
GUT (2017)
Management Strategies to Improve Outcomes of Patients With Inflammatory Bowel Diseases
Jean-Frederic Colombel et al.
GASTROENTEROLOGY (2017)
Early intervention in Crohn's disease: towards disease modification trials
Silvio Danese et al.
GUT (2017)
Impact of the early use of immunomodulators or TNF antagonists on bowel damage and surgery in Crohn's disease
E. Safroneeva et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2015)
Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial
Reena Khanna et al.
LANCET (2015)
Adalimumab Induces Deep Remission in Patients With Crohn's Disease
Jean-Frederic Colombel et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2014)
Effects of Vedolizumab Induction Therapy for Patients With Crohn's Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed
Bruce E. Sands et al.
GASTROENTEROLOGY (2014)
Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial
Laurent Peyrin-Biroulet et al.
GUT (2014)
Subgroup analysis of the placebo-controlled CHARM trial: Increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease
S. Schreiber et al.
JOURNAL OF CROHNS & COLITIS (2013)
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Development of the Paris Definition of Early Crohn's Disease for Disease-Modification Trials: Results of an International Expert Opinion Process
Laurent Peyrin-Biroulet et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2012)
Risk Factors Associated With Progression to Intestinal Complications of Crohn's Disease in a Population-Based Cohort
Kelvin T. Thia et al.
GASTROENTEROLOGY (2010)
Early Crohn disease: a proposed definition for use in disease-modification trials
Laurent Peyrin-Biroulet et al.
GUT (2010)
A review of activity indices and efficacy Endpoints for clinical trials of medical therapy in adults with Crohn's disease
WJ Sandborn et al.
GASTROENTEROLOGY (2002)
Share Paper
